Cipher Pharmaceuticals announces Ozenoxacin accepted for review by Health Canada
"This represents another important milestone on our path to commercialization of this alternative treatment for one of the most common bacterial skin infections in children – a condition that has become more challenging with the emergence of treatment-resistant bacterial pathogens," said Joan Chypyha,
Ozenoxacin belongs to a new generation of non-fluorinated quinolones that have demonstrated improved tolerability and safety over fluorinated quinolones. Phototoxicity, photoallergenic sensitization and articular toxicity were not observed in local tolerability studies1. Ozenoxacin also demonstrated in vitro and in vivo antibacterial activity against a broad range of pathologically relevant bacteria, including methicillin resistant Staphylococcus aureus (MRSA) strains and clinical isolates of organisms with emerging resistance to quinolones and other topical antibiotics.
In
About Ferrer
Founded in 1959, Ferrer is a privately-held Spanish pharmaceutical company. It is present in more than 90 countries, with 23 international affiliates. Ferrer is active in the pharmaceutical, health, fine chemicals and food sectors; key areas for contributing to people's health and quality of life. The main therapeutic areas covered by Ferrer's pharmaceutical production are dermatology, cardiovascular, CNS, cancer, gastrointestinal, analgesics, bone metabolism, anti-infectives, immunology, diagnostics, OTC and dermocosmetics. www.ferrer.com
About
Cipher completed seven transactions in 2015, including the acquisition of Innocutis and its nine branded dermatology products, to build its
Forward-Looking Statements
Statements made in this news release may be forward-looking and therefore subject to various risks and uncertainties. The words "may", "will", "could", "should", "would", "suspect", "outlook", "believe", "plan", "anticipate", "estimate", "expect", "intend", "forecast", "objective", "hope" and "continue" (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Factors that could cause results to vary include those identified in the Company's Annual Information Form, Form 40-F and other filings with Canadian and
1
SOURCE


Small SUVs do poorly in insurance industry headlight tests
Advisor News
- SEC settlement would require Tai Lopez, two others, to pay $6.8 million
- The Gen Z money paradox
- NAIFA applauds final SECURE 2.0 regulations
- What will Democrats in Congress do about healthcare and retirement?
- Election results cloud retirement legislation outlook, experts say
More Advisor NewsAnnuity News
- Best’s Market Segment Report: AM Best Maintains Stable Outlook on US Life/Annuity Insurance Segment
- AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
- Boomers want retirement protection, but their actions don’t match their mindset
- NAIC task force to address LTC riders
- ‘It’s really shocking:’ Regulators scrutinize assets backing annuity sellers
More Annuity NewsHealth/Employee Benefits News
- 'Everybody missed this': Nevada's state worker insurance mismanaged for years, officials say
- Picking Medicare insurance plan is daunting task – Healthful Hints
- November Issue of Best’s Review Ranks US Life Reinsurers and More
- New York Life Announces Record $3.1 Billion in Policy Owner Dividends for 2027
- New Va. subsidies help lure people back to health insurance
More Health/Employee Benefits NewsLife Insurance News
- November Issue of Best’s Review Ranks US Life Reinsurers and More
- Nebraska widow’s big win against life insurer in legal limbo
- New York Life Announces Record $3.1 Billion in Policy Owner Dividends for 2027
- AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
- U-Haul Holding Company to Participate in Deutsche Bank Conference
More Life Insurance News